Vaxart (STU:NB11) Moat Score: 4/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NB11 Vaxart Inc STU:NB11
63 GF Score
Price €0.60
GF Value €9.39
! 3 Warning Signs
View Full Analysis

What is Vaxart Moat Score?

Vaxart STU:NB11 63 Moat Score is 4 as of Jul. 18, 2026. GuruFocus rates STU:NB11 with a GF Score™ of 63/100 and a GF Value™ of €9.39. The stock has 3 warning signs investors should review. Among 1,396 Biotechnology companies, Vaxart ranks better than 88.75% on this metric.

Vaxart has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Vaxart has Narrow Moat: Vaxart Inc has some potential in the biotech sector due to its innovative oral vaccine platform. However, it faces significant competition and lacks strong brand strength or regulatory barriers, resulting in a discernible but modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vaxart might have Narrow Moat - Discernible but modest moat.

Vaxart  (STU:NB11) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vaxart Moat Score Related Terms

STU:NB11 vs SPRO, ADCT, GNLX: Moat Score Comparison

For the Biotechnology subindustry, Vaxart's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Moat Score distribution charts can be found below:

* The bar in red indicates where Vaxart's Moat Score falls into.


STU:NB11
63GF Score
Vaxart Inc STU:NB11
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Vaxart (STU:NB11) has a Moat Score of 4 as of Jul. 18, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vaxart ranks #157 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Vaxart's Moat Score too high?
Vaxart's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Vaxart's value of 4 is 100% above this industry median. Based on the distribution chart, Vaxart ranks #157 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vaxart has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Moat Score compare to SPRO and ADCT?
According to the Biotechnology industry distribution chart, Vaxart ranks #157 out of 1396 companies for Moat Score. This places Vaxart in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Vaxart's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxart's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxart's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (STU:NB11) has a current Moat Score of 4. The stock's GF Value™ is €9.39, compared to a current price of €0.60 — trading 93.6% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Vaxart's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vaxart (STU:NB11), the current Moat Score is 4 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaxart (STU:NB11) Overvalued in 2026?

Based on GuruFocus' analysis, Vaxart stock appears to be undervalued. The current stock price of €0.60 is trading 93.6% below its estimated GF Value™ of €9.39.

Key valuation signals for STU:NB11:

  • Moat Score: 4
  • GF Value™: €9.39 vs. price of €0.60 (93.6% below fair value)
  • GF Score™: 63/100 with 3 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1396)

No single metric tells the full story. See the STU:NB11 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
63GF Score

Get the complete analysis for STU:NB11

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€9.39
GF Value